###begin article-title 0
###xml 40 48 40 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(UCHL1) </italic>
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease
###end article-title 0
###begin p 1
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i.e</italic>
###xml 382 388 382 388 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 499 505 499 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 683 689 683 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 702 707 702 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
###xml 846 848 840 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 884 890 878 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 980 986 974 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 551 559 <span type="species:ncbi:9606">patients</span>
Alzheimer's disease (AD) is characterized by protein aggregates, i.e. senile plaques and neurofibrillary tangles. The ubiquitin-proteasome system has been proposed a role in proteolytic removal of these protein aggregates. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is a de-ubiquitinating enzyme with important functions in recycling of ubiquitin. The S18Y polymorphism of the UCHL1 gene confers protection against Parkinson's disease. In this study, the genotype and allele frequencies of the UCHL1 S18Y polymorphism were investigated in 452 AD patients and 234 control subjects, recruited from four memory clinics in Sweden. Using a binary logistic regression model including UCHL1 allele A and APOE epsilon4 allele positivity, age and sex as covariates with AD diagnosis as dependent variable, an adjusted OR of 0.82 ([95% CI 0.55-1.24], P = 0.35) was obtained for a positive UCHL1 allele A carrier status. The present study thus do not support a protective effect of the UCHL1 S18Y polymorphism against AD.
###end p 1
###begin title 2
Findings
###end title 2
###begin p 3
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 744 745 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 746 747 746 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 1008 1009 1008 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 1010 1011 1010 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 1203 1204 1203 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 1358 1359 1358 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 927 932 <span type="species:ncbi:9606">human</span>
Aggregation of aberrant proteins is a hallmark of several neurodegenerative diseases, including Alzheimer's (AD), Huntington's (HD) and Parkinson's (PD) diseases. In this context, the ubiquitin-proteasome system (UPS) has been ascribed a central role in preventing the formation of pathological protein aggregates by proteolytic removal of defect proteins [1]. Proteins destined for degradation by the UPS are labelled with a 76-amino acid peptide, ubiquitin, through a series of conjugation steps by the E1, E2 and E3 enzymes respectively. There are also two classes of de-ubiquitinating enzymes; the ubiquitin-specific processing proteases (UBPC) and the ubiquitin carboxy-terminal hydrolase family (UHC). For recent reviews on the UPS, see [2,3]. Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) is an isoform of the UHC group, expressed mainly in neurons and testis/ovary. However, UCHL1 has also been found in cells of the human diffuse neuroendocrine system and is expressed is several forms of cancer [4-6]. UCHL1 has an important role in recycling of ubiquitin through hydrolysis of peptide-ubiquitin bonds and processing of ubiquitin precursors, but it also possesses ubiquitin ligase activity [7]. Moreover, it has been shown that UCHL1 associates with monoubiquitin and elongates its half-life, thus ensuring stability of ubiquitin within neurons [8].
###end p 3
###begin p 4
###xml 32 38 32 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 194 195 194 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 420 422 420 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 464 470 464 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
Several genetic variants of the UCHL1 gene have been described; both those leading to gain-of-function and those resulting in loss-of-function. The I93 M mutant results in 50% reduced activity [9], whereas the S18Y variant exhibits increased hydrolytic activity [10]. Other studies showed comparable hydrolase activity of the UCHL1 S18Y variant when compared to the wild type enzyme, but a reduction in ligase activity [11]. It has also been demonstrated that the UCHL1 S18Y polymorphism has a specific ability to act as a potent antioxidant in neuronal cell culture systems [12].
###end p 4
###begin p 5
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 132 134 132 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 194 200 194 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 277 279 277 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 591 597 591 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 364 372 <span type="species:ncbi:9606">patients</span>
###xml 447 459 <span type="species:ncbi:9606">participants</span>
A number of reports have demonstrated a protective effect of the S18Y polymorphism against sporadic PD in different populations [13-16], although conflicting data exist [17]. As for AD, data on UCHL1 genotype frequencies and its effect on risk of AD is scarce and conflicting [18,19]. The purpose of this study was to investigate the UCHL1 S18Y polymorphism in AD patients and controls in the Swedish population. Given that we, for subsets of the participants, have previously collected data on levels of CSF biochemical markers and neuropathological scores for AD, associations between the UCHL1 S18Y polymorphism and these variables could be investigated in addition to the genetic risk analysis.
###end p 5
###begin p 6
###xml 965 967 965 967 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 968 970 968 970 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 38 46 <span type="species:ncbi:9606">patients</span>
###xml 125 133 <span type="species:ncbi:9606">patients</span>
###xml 231 239 <span type="species:ncbi:9606">patients</span>
###xml 268 276 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 684 692 <span type="species:ncbi:9606">patients</span>
The study population consisted of 452 patients with AD and 234 subjects without dementia, all of Swedish nationality. The AD patients and control subjects were recruited and diagnosed from four memory clinics in Sweden; Malmo (371 patients, 48 controls), Huddinge (52 patients, 70 controls), Goteborg/Molndal (29 patients, 95 controls) and Linkoping (21 controls). The patients were invited to participate at their first visit to the respective clinic, where they also gave their informed consent. The control subjects were recruited by advertisement in the local newspapers or at senior citizen organization meetings. A few of these controls were spouses or unrelated friends of the patients. The study was approved by the local Ethical Commissions at the respective academic center and the tenets of the Declaration of Helsinki were followed. Parts of the AD and the control groups in this work have also been included in previous studies on other polymorphisms [20,21].
###end p 6
###begin p 7
###xml 7 15 <span type="species:ncbi:9606">patients</span>
All AD patients underwent clinical examination, neuropsychological evaluations including Mini-Mental State Examinaton (MMSE), computed tomography (CT) or magnetic resonance imaging (MRI) of the brain and routine blood analyses. The healthy elderly controls were classified as non-demented on the basis of a structured interview performed by a research nurse that included information on health history, lifestyle-related variables and psychosocial situation. Only controls with an MMSE score of at least 26 were included in the study. In addition, 65 years was set as the youngest age of controls for participation in the study.
###end p 7
###begin p 8
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 644 648 644 648 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">181 </sub>
###xml 654 657 654 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">181</sub>
###xml 668 673 665 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1-42 </sub>
###xml 987 992 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
###xml 1101 1103 1098 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
###xml 705 713 <span type="species:ncbi:9606">patients</span>
###xml 862 870 <span type="species:ncbi:9606">patients</span>
Patients were clinically diagnosed with probable late-onset AD according to the NINCDS-ADRDA criteria [22] by a dementia investigation team that included specialists in geriatric medicine and psychiatry. To avoid inclusion of cases with familial Alzheimer's disease (FAD) only patients 60 years of age or older were included in the study. In addition, all patients were questioned about their family history regarding AD and those with suspect heredity were excluded. Individuals with significant psychiatric or somatic diseases other than AD were excluded. Data on CSF biomarkers, including the concentrations of total-tau (T-tau), phospho-tau181 (P-tau181) and Abeta1-42 was available for 260 of the AD patients and 117 of the controls. Neuropathological diagnosis and scores based on senile plaques and neurofibrillary tangles were available for 65 of the AD patients and 80 of the controls. Genomic DNA was extracted from whole blood samples and brain tissue using standard methods. APOE (gene map locus 19q13.2) genotyping had previously been performed by minisequencing, as described in detail [23].
###end p 8
###begin p 9
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 253 257 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#174; </sup>
###xml 382 383 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 821 827 786 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 1027 1033 992 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
The UCHL1 (gene map locus 4p14; [Entrez gene ID: 7345]) S18Y, 54C>A polymorphism (rs5030732) was analyzed using the Dynamic Allele Specific Amplification (DASH) tehnology as described earlier [24]. The PCR were carried out with HotStarTaq DNA Polymerase(R) (QIAGEN, Hilden, Germany) in a final volume of 25 mul, containing 5-20 ng of template DNA. Optimal conditions were: 1 mM MgCl2, 0.2 mM dNTPs, 0.02 U Taq polymerase, 0.16 pmol/mul of the forward biotinylated primer (5'Biotin-GCCGCCTTGTCTCCTCTCAGCAG3') and 0.78 pmol/mul of the reverse primer (5'GTCACTGGCCTGCGACCCC3'), (Invitrogen, Paisley, UK) in 1 x PCR buffer (Roche, Mannheim, Germany). The cycling profile was: 15 min at 95degreesC, then 39 cycles: 30 sec at 95degreesC, 45 sec at 60degreesC, 45 sec at 72degreesC and finally 10 min at 72degreesC. To identify UCHL1 alleles the probe 5'GACAGAAACGCACTTGT-Rox3' (MWG Biotech, London, United Kingdom) was used. The accuracy of the DASH method was verified by DNA sequencing of 15 individuals representing the different UCHL1 genotypes (five of each genotype).
###end p 9
###begin p 10
###xml 218 220 216 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 226 227 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 280 286 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 457 462 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
###xml 535 537 527 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Primary analyses compared differences between the AD patients and control subjects regarding age, sex, MMSE score, biochemical markers, neuropathological scores, genotype and allele frequencies using Fisher's exact chi2 test, t-test and Mann-Whitney U test. Secondary analysis of UCHL1 allele A-carrier status was performed with a binary logistic regression model with diagnosis (AD versus control) as dependent variable and allele positivity, age, sex and APOE epsilon4 allele status as independent variables. Significance was set at P < 0.05. SPSS 16.0 (SPSS Inc, Chicago, Il) was used as statistic software.
###end p 10
###begin p 11
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 353 358 353 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
###xml 95 100 <span type="species:ncbi:9606">women</span>
###xml 201 206 <span type="species:ncbi:9606">women</span>
In the AD group the mean age was 76.2 (SD 6.4) years (range 60-102 years) and 299 (66.2%) were women. In the control group the mean age was 75.9 (SD 7.1) years (range 65-94 years) and 127 (58.8%) were women. A summary of demographic and clinical characteristics is presented in table 1, including MMSE score, CSF biomarkers, neuropathological score and APOE epsilon4 allele-carrier status.
###end p 11
###begin p 12
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Demographic, clinical and genetic characteristics of patients with AD and controls
###end p 12
###begin p 13
###xml 22 28 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
*Fisher's Exact Test, daggerMann-Whitney U-test. AD = Alzheimer's disease, SD = Standard Deviation, MMSE = Mini Mental State Examination, Abeta = beta-amyloid, SPs = senile plaques, NFTs = neurofibrillary tangles
###end p 13
###begin p 14
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 448 454 448 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 695 697 695 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 713 715 713 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 734 736 734 736 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 781 783 781 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 799 801 799 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 820 822 820 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 375 383 <span type="species:ncbi:9606">patients</span>
Genotype and allele frequencies for the UCHL1 S18Y polymorphism are shown in table 2. There was a significant overrepresentation of the heterozygous genotype (AC) in the control group (p = 0.03). There were no significant differences between the controls and the cases with regard to the homozygous genotypes however, even if the CC genotype was overrepresented among the AD patients with a border-line p-value (0.054). In addition, when analyzing UCHL1 allele A-carrier status (dominant approach) a positive allele A-carrier status was slightly overrepresented in the control group (p = 0.054). The distributions of the UCHL1 genotypes were in Hardy-Weinberg equilibrium for the control group (P = 0.602 for AA, P = 0.692 for AC and P = 0.846 for CC) as well as for the AD group (P = 0.436 for AA, P = 0.647 for AC and P = 0.825 for CC).
###end p 14
###begin p 15
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
UCHL1 genotype and allele frequencies in patients with AD and controls
###end p 15
###begin p 16
###xml 22 28 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8224;</sup>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
*Fisher's Exact Test, daggerThere are two alleles per subject, yielding n = 904 for AD patients and n = 468 for controls. AD = Alzheimer's disease.
###end p 16
###begin p 17
###xml 51 57 51 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
###xml 214 216 208 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
###xml 252 258 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 289 290 283 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 329 335 323 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 405 407 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 526 530 520 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">181 </sub>
###xml 538 543 529 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1-42 </sub>
###xml 575 581 566 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 606 607 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 727 733 718 724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 753 754 744 745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 782 788 773 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
Using a binary logistic regression model including UCHL1 allele A and APOE epsilon4 allele positivity, age and sex as covariates with AD diagnosis as dependent variable, an adjusted OR of 0.82 ([95% CI 0.55-1.24], P = 0.35) was obtained for a positive UCHL1 allele A carrier status (table 3). On the basis of previously reported UCHL1 allele frequencies, a standardized difference of 0.29 was calculated [15]. This yielded a power of the study of 96%, indicating that the lack of association was not spurious. CSF T-tau, P-tau181 or Abeta1-42 levels were not affected by the UCHL1 S18Y polymorphism (Table 4). Neither did neuropathological scores of senile plaques and neurofibrillary tangles exhibit any associations with the UCHL1 polymorphism (Table 4). Further, we compared the UCHL1 allele A-positivity for AD patients and control subjects respectively between the different centers and found no differences (not shown).
###end p 17
###begin p 18
###xml 50 56 50 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 70 75 70 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE </italic>
Binary logistic regression of AD diagnosis versus UCHL1 allele A- and APOE allele epsilon4-carrier status, age and gender.
###end p 18
###begin p 19
AD = Alzheimer's disease, B = Regression coefficient, S.E. = Standard error, OR = Adjusted odds ratio, CI = Confidence interval
###end p 19
###begin p 20
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 94 102 <span type="species:ncbi:9606">patients</span>
CSF biomarkers and neuropathological score in relation to UCHL1 allele A-carrier status in AD patients and control subjects
###end p 20
###begin p 21
CSF = cerebrospinal fluid, AD = Alzheimer's disease, SPs = senile plaques, NFTs = neurofibrillary tangles, Abeta = beta-amyloid, *Mann-Whitney U-test
###end p 21
###begin p 22
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 493 495 493 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 696 698 696 698 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 699 701 699 701 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 844 846 841 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 686 694 <span type="species:ncbi:9606">patients</span>
###xml 831 836 <span type="species:ncbi:10090">mouse</span>
Aggregation of proteins is a major feature of several neurodegenerative disorders, including Alzheimer's disease (AD). Several lines of evidence suggest that the ubiquitin-proteasome system (UPS) is involved in the pathogenesis of AD [1]. Accumulation of ubiquitin in senile plaques and neurofibrillary tangles [25-28], changes in proteasome subunit composition in AD [29] and an association of AD with polymorphic variants of UBQLN1, encoding for ubiquilin which is a ubiquitin-like protein [30], are some of the signs pointing towards a role of the UPS in AD. Of special interest is the finding that UCHL1 is oxidized in AD and that it is down-regulated in affected brain areas of AD patients [31,32]. Also interesting is the finding that exogenous UCHL1 ameliorated beta-amyloid-induced synaptic and memory dysfunction in an AD mouse model [33].
###end p 22
###begin p 23
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 311 313 311 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 602 608 602 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 626 628 626 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 747 753 747 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35">35</xref>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
The S18Y polymorphism of the UCHL1 gene is associated with lower incidence of Parkinson's disease [13-16]. The mechanism for this protective effect is not known, but it may be at least partially explained by the increased antioxidative capacity demonstrated in neuronal cells expressing the UCHL1 S18Y variant [12]. Little is known about its effect on AD prevalence. A Chinese study has demonstrated lower frequencies of the A allele and the AA genotype in female AD patients as compared to female controls [19]. However, a genetic study in a Colombian population could not find an association between UCHL1 genotypes and AD [18]. The number of genome-wide association studies in the AD field has increased rapidly; none of these has reported the UCHL1 S18Y polymorphism among the significant SNPs found however [34,35].
###end p 23
###begin p 24
###xml 43 49 43 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">UCHL1 </italic>
The allele and genotype frequencies of the UCHL1 S18Y polymorphism seen in this study are in accordance with previous results in Swedish populations [13]. The present study do not support a role of the UCHL1 S18Y polymorphism AD however.
###end p 24
###begin title 25
Competing interests
###end title 25
###begin p 26
The authors declare that they have no competing interests.
###end p 26
###begin title 27
Authors' contributions
###end title 27
###begin p 28
MZ participated in the design of the study, analyzed the data statistically and drafted the manuscript. AS performed genetic analyses and helped to draft the manuscript. MvO, MSP and SL performed genetic analyses and revised the manuscript critically. LM, AW and NA collected clinical material and revised the manuscript critically. KB participated in the design of the study and revised the manuscript critically. HZ conceived of the study, helped in analyzing the data and helped in drafting the manuscript.
###end p 28
###begin p 29
All authors have read and approved the final manuscript.
###end p 29
###begin title 30
Acknowledgements
###end title 30
###begin p 31
This work was supported by grants from the Swedish Research Council, the Royal Swedish Academy of Sciences, the Sahlgrenska University Hospital, the Goteborg Medical Society, Swedish Brain Power, Hjalmar Svenssons forskningsfond, Stiftelsen for Gamla Tjanarinnor and Alzheimerfonden.
###end p 31
###begin article-title 32
The ubiquitin-proteasome system in Alzheimer's disease
###end article-title 32
###begin article-title 33
The ubiquitin system, disease, and drug discovery
###end article-title 33
###begin article-title 34
Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction
###end article-title 34
###begin article-title 35
Neural markers in carcinoma of the lung
###end article-title 35
###begin article-title 36
###xml 93 98 <span type="species:ncbi:9606">human</span>
Expression of protein gene product 9.5 (PGP9.5)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells
###end article-title 36
###begin article-title 37
PGP 9.5--a new marker for vertebrate neurons and neuroendocrine cells
###end article-title 37
###begin article-title 38
Genetic causes of Parkinson's disease: UCHL-1
###end article-title 38
###begin article-title 39
Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron
###end article-title 39
###begin article-title 40
The ubiquitin pathway in Parkinson's disease
###end article-title 40
###begin article-title 41
The functions of UCH-L1 and its relation to neurodegenerative diseases
###end article-title 41
###begin article-title 42
The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility
###end article-title 42
###begin article-title 43
The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells
###end article-title 43
###begin article-title 44
S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden
###end article-title 44
###begin article-title 45
S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship
###end article-title 45
###begin article-title 46
Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease
###end article-title 46
###begin article-title 47
UCHL1 is a Parkinson's disease susceptibility gene
###end article-title 47
###begin article-title 48
Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease
###end article-title 48
###begin article-title 49
Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND UCHL1) in Alzheimer's disease in Colombia
###end article-title 49
###begin article-title 50
Genetic association between Ubiquitin Carboxy-terminal Hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population
###end article-title 50
###begin article-title 51
Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease
###end article-title 51
###begin article-title 52
Association of complement factor H Y402H gene polymorphism with Alzheimer's disease
###end article-title 52
###begin article-title 53
###xml 128 133 <span type="species:ncbi:9606">Human</span>
Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
###end article-title 53
###begin article-title 54
No association between the alpha2-macroglobulin (A2 M) deletion and Alzheimer's disease, and no change in A2 M mRNA, protein, or protein expression
###end article-title 54
###begin article-title 55
Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation
###end article-title 55
###begin article-title 56
Immunocytochemical co-localization of the proteasome in ubiquitinated structures in neurodegenerative diseases and the elderly
###end article-title 56
###begin article-title 57
Ubiquitin is a component of paired helical filaments in Alzheimer's disease
###end article-title 57
###begin article-title 58
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains
###end article-title 58
###begin article-title 59
Ultrastructural localization of beta-amyloid, tau, and ubiquitin epitopes in extracellular neurofibrillary tangles
###end article-title 59
###begin article-title 60
Immunoproteasome and LMP2 polymorphism in aged and Alzheimer's disease brains
###end article-title 60
###begin article-title 61
Family-based association between Alzheimer's disease and variants in UBQLN1
###end article-title 61
###begin article-title 62
Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1
###end article-title 62
###begin article-title 63
Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia
###end article-title 63
###begin article-title 64
Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory
###end article-title 64
###begin article-title 65
Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease
###end article-title 65
###begin article-title 66
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease
###end article-title 66

